Epilepsy Talk
What’s really in your meds?
1 Comment
As Americans become more concerned about quality issues with prescription medications made abroad, one company is trying to offer an additional layer of reassurance — by doing chemical analysis before dispensing drugs to patients.
Tags: anti-convulsant medications, chemical analysis, China, consistency, contaminents, correct dosage, FDA, generics and name brand drugs, global drug supply, India, level of quality control, media attention, pharmaceutical supply chain, prescription medications, quality data, quality issues, quality scores, ranking manufacturers, relapses, safety, side effects, third-party check, variability
Stop the FDA from regulating supplements and nutrients
8 Comments
The Dietary Supplement Labeling Act pretends to be consumer-oriented, but instead will give the FDA redundant power that it could easily misuse, restricting your access to nutritional supplements and raising the cost of buying them.
In short, nutritional supplements will be regulated like prescription drugs…
Tags: consumer interests, FDA, nutritional supplements, unnecessary legislation
$56,000 a year for an unproven drug!
Leave a Comment
Getting the FDA to retract a decision, is like getting the toothpaste back in the tube, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Whether it’s “yes” or “no,” there is no “maybe so”.
Tags: $56000 a year, aducanumab, Alzheimer’s, efficiency, FDA, not proven, patients, risk, side-effects
What Is the FDA Thinking?
3 Comments
Getting the FDA to retract a decision is like getting the toothpaste back into the tube, once it’s been squeezed out.
Take the current all-star Alzheimer’s drug aducanumab. It’s not a proven but it IS approved. To the hefty price tag of $56,000 a year!
$112 billion new Alzheimer’s drug in question
4 Comments
Getting the FDA to retract a decision is like getting the toothpaste back in the tub, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all star Alzheimer’s drug aducanumab.
Tags: $112 billion costs, &56000 a year, alzheimer's, FDA, Medicare, not proven, side effects
The first new Alzheimer’s drug in 18 years may not work.
Leave a Comment
Getting the FDA to retract a decision is like getting the toothpaste back in the tub, after it’s been squeezed out…
Whether it’s “yes” or “no,” there is no “maybe so”.
A good example is the new all-star Alzheimer’s drug aducanumab.
Tags: $5600 a year, aducanumab, Alzheimer's drug, amyloid plaque, billions of dollars, caregiver, FDA, Medicare, not proven
Medical Marijuana — It’s Here to Stay…
14 Comments
Let’s face it. The time has come.
Even the FDA has opened its eyes with new clinical trials.
Although the AMA chooses to keep their heads in the sand. For now.
It used to be popular to debate the merits and dangers of medical marijuana.
For example, it could lead to addiction. Like cocaine. (Oh please!)
But now, there’s clinically proven scientific proof, with more to come…
Can I Substitute Generic Drugs for My Anti-Seizure Medications?
35 Comments
The controversy about generic drugs continues…
About the author
Epilepsy Talk 